{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:27:57Z","timestamp":1778092077706,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vaccine.2022.09.077","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T07:33:30Z","timestamp":1666424010000},"page":"7014-7021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine"],"prefix":"10.1016","volume":"40","author":[{"given":"Lidia","family":"Serra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Webber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Burman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Bueti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gorruso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Mather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.09.077_b0005","unstructured":"World Health Organization. Meningococcal Meningitis, http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/meningococcal-meningitis; 2018 [accessed August 1, 2019]."},{"key":"10.1016\/j.vaccine.2022.09.077_b0010","unstructured":"Nimenrix (meningococcal groups A, C, W-135, and Y conjugate vaccine). Summary of Product Characteristics, Pfizer Ltd, Sandwich, Kent, UK; 2021."},{"key":"10.1016\/j.vaccine.2022.09.077_b0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/fmb-2018-0343","article-title":"Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence","volume":"14","author":"Findlow","year":"2019","journal-title":"Future Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.077_b0020","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12879-020-05104-5","article-title":"A phase 2b\/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years","volume":"20","author":"Borja-Tabora","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.09.077_b0025","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1080\/21645515.2020.1746110","article-title":"Ten-year antibody persistence and booster response to MenACWY-TT vaccine after primary vaccination at 1\u201310 years of age","volume":"16","author":"Vesikari","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.09.077_b0030","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2018.04.064","article-title":"Antibody persistence and booster response 68 months after vaccination at 2\u201310 years of age with one dose of MenACWY-TT conjugate vaccine","volume":"36","author":"Knuf","year":"2018","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.09.077_b0035","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1080\/21645515.2020.1744363","article-title":"Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine","volume":"16","author":"Quiambao","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.09.077_b0040","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1016\/j.vaccine.2020.02.048","article-title":"Persistence of bactericidal antibodies following primary and booster MenACWY-TT vaccination of toddlers: a review of clinical studies","volume":"38","author":"Webber","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.09.077_b0045","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1097\/INF.0000000000001484","article-title":"Safety and immunogenicity of the quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine coadministered with routine childhood vaccines in European infants: an open, randomized trial","volume":"36","author":"Merino Arribas","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.09.077_b0050","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40266-013-0065-0","article-title":"Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 years and older: results of an open-label, randomized, controlled trial","volume":"30","author":"Dbaibo","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.vaccine.2022.09.077_b0055","unstructured":"GlaxoSmithKline. Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV\/Hib Vaccines, https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=113369; 2019 [accessed November 23, 2021]."},{"issue":"14","key":"10.1016\/j.vaccine.2022.09.077_b0060","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.vaccine.2018.02.013","article-title":"Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: a phase III, open-label, randomised study","volume":"36","author":"Cutland","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.09.077_b0065","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.4161\/hv.22165","article-title":"A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2\u201310 years","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2022.09.077_b0070","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00431-012-1924-0","article-title":"Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2\u201310-year-old children: results of an open, randomised, controlled study","volume":"172","author":"Knuf","year":"2013","journal-title":"Eur J Pediatr"},{"issue":"4","key":"10.1016\/j.vaccine.2022.09.077_b0075","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","article-title":"Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile","volume":"30","author":"Memish","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.09.077_b0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","author":"Ostergaard","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.077_b0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jpids\/pit058","article-title":"Comparison of the safety and immunogenicity of a novel quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine and a marketed quadrivalent meningococcal ACWY-diphtheria toxoid conjugate vaccine in healthy individuals 10\u201325 years of age","volume":"3","author":"Halperin","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2022.09.077_b0090","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.09.077_b0095","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1586\/14760584.5.5.651","article-title":"Nasopharyngeal colonization: a target for pneumococcal vaccination","volume":"5","author":"K\u00e4yhty","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"17","key":"10.1016\/j.vaccine.2022.09.077_b0100","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.vaccine.2018.02.085","article-title":"Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: results of a phase III, open, non-randomized study","volume":"36","author":"Klein","year":"2018","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22011975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22011975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:19:16Z","timestamp":1759403956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22011975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":20,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0264410X22011975"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.077","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Pfizer Inc and The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}